# Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Naiyer A. Rizvi,Julien Mazières,David Planchard,Thomas E. Stinchcombe,Grace K. Dy,Scott Antonia,Leora Horn,H. Léna,Elisa Minenza,B. Mennecier,Gregory A. Otterson,Luis T. Campos,David R. Gandara,Benjamin Levy,Suresh Nair,Gérard Zalcman,Jürgen Wolf,Pierre‐Jean Souquet,Editta Baldini,Federico Cappuzzo,C. Chouaïd,Afshin Dowlati,Rachel E. Sanborn,Ariel López-Chávez,Christian Grohé,Rudolf M. Huber,Christopher Harbison,Christine Baudelet,Brian Lestini,Suresh S. Ramalingam |
| Citations | 1,434 |
| DOI | 10.1016/s1470-2045(15)70054-9 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2106511606 |
| PMID | 25704439 |
| Type | article |
| Year | 2015 |

## Paper authors

- [David Planchard](https://scholariq.org/researchers/david-planchard/)
- [Afshin Dowlati](https://scholariq.org/researchers/afshin-dowlati/)
- [Julien Mazières](https://scholariq.org/researchers/julien-mazieres/)
- [Christian Grohé](https://scholariq.org/researchers/christian-grohe/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.